Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 152

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 152
---
 over 30 years of direct spine and orthopedics industry experience. Mr. Valentine
has served as President, Chief Executive Officer and member of the board of directors of Intrinsic Therapeutics, Inc., or Intrinsic Therapeutics,
a medical technology company driving to change the standard of care for lumbar discectomy patients with large annular defects by reducing
reoperations for reherniations, since May 2025. Prior to joining Intrinsic Therapeutics, Mr. Valentine was most recently President and
Chief Executive Officer of Orthofix, Inc. (Nasdaq: OFIX), a global spine and orthopedics company, following its merger with SeaSpine,
Inc., or SeaSpine, in 2023. Prior to the merger in 2023, Mr. Valentine served as Chief Executive Officer and President of SeaSpine, a
global medical technology company focused on the design, development, and commercialization of surgical solutions for the treatment of
spinal disorders, beginning in 2015. Prior to joining SeaSpine, Mr. Valentine served in various leadership capacities at NuVasive, Inc.
from 2001 to 2015, including, most recently, as President and Chief Operating Officer, and before that, in senior executive roles in
marketing, development and operations. From 1992 through 2000, Mr. Valentine held leadership positions with Medtronic Spine LLC, most
recently as that company’s Vice President of Marketing. He currently serves as Chairman of the board of directors of LocateBio
Ltd., a private UK MedTech company with industry-leading rhBMP-2 delivery and tissue scaffold capabilities. Mr. Valentine has served
as a director of Alphatec Holdings, Inc. (Nasdaq: ATEC), or Alphatec, since July 2024. Prior to his time as a director of Alphatec, Mr.
Valentine served as special advisor to their board of directors from October 2023 until his election in 2024. Mr. Valentine previously
served on the board of directors of SI-Bone, Inc (Nasdaq: SIBN), a developer of minimally invasive surgical treatments for sacroiliac
joint disorders and sacral fixation for spine surgery, from 2015 until 2024. Mr. Valentine holds a B.B.A. degree in Management and Biomedical
Sciences from Western Michigan University.

Mr. Efraim Cohen-Arazi,